Atara Biotherapeutics, Inc. (ATRA) financial statements (2022 and earlier)

Company profile

Business Address 611 GATEWAY BLVD
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments371501259310166256320
Cash and cash equivalents1062007461794824
Short-term investments26530018524987208297
Restricted cash and investments0000   
Receivables11     
Other undisclosed current assets12211412654
Total current assets:385523273321172261325
Noncurrent Assets
Operating lease, right-of-use asset261214
Property, plant and equipment545154694430
Restricted cash and investments11111  
Other noncurrent assets2111000
Total noncurrent assets:846570704630
TOTAL ASSETS:468588343392218264325
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities432823142075
Accounts payable177841531
Accrued liabilities     11
Employee-related liabilities25201511643
Deferred revenue4133 
Debt   00  
Other liabilities96663  
Other undisclosed current liabilities1316819425
Total current liabilities:106833740281010
Noncurrent Liabilities
Long-term debt and lease obligation26131401  
Capital lease obligations01  
Operating lease, liability261314
Liabilities, other than long-term debt57301    
Deferred revenue5628 
Other liabilities221    
Other undisclosed noncurrent liabilities   131210
Total noncurrent liabilities:834315131210
Total liabilities:1891265253401010
Stockholders' equity
Stockholders' equity attributable to parent280462291339178254315
Common stock0000000
Additional paid in capital1,7451,5871,109867475431414
Accumulated other comprehensive income (loss)(0)00(0)(0)(0)(1)
Accumulated deficit(1,465)(1,125)(818)(527)(297)(177)(98)
Total stockholders' equity:280462291339178254315
TOTAL LIABILITIES AND EQUITY:468588343392218264325

Income statement (P&L) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Gross profit:     (5)(5)
Operating expenses(361)(309)(296)(237)(122)(81)(58)
Other undisclosed operating income20    55
Operating loss:(340)(309)(296)(237)(122)(81)(58)
Nonoperating income
(Other Nonoperating income)
0256221
Interest and debt expense(0)(0)(0)    
Loss from continuing operations before equity method investments, income taxes:(340)(307)(291)(231)(120)(79)(57)
Other undisclosed income from continuing operations before income taxes000    
Loss from continuing operations before income taxes:(340)(307)(291)(231)(120)(79)(57)
Income tax expense (benefit)(0)(0)(0)00(0)0
Net loss available to common stockholders, diluted:(340)(307)(291)(231)(119)(79)(57)

Comprehensive Income ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(340)(307)(291)(231)(119)(79)(57)
Comprehensive loss:(340)(307)(291)(231)(119)(79)(57)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(1)01(0)00(0)
Comprehensive loss, net of tax, attributable to parent:(341)(307)(290)(231)(119)(79)(58)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: